

AMENDMENTS TO THE CLAIMS

26. (currently amended) A ~~[[P]]~~process for the production of a dimeric, biologically active Transforming Growth Factor type $\beta 2$ (TGF- $\beta 2$) or $\beta 3$ (TGF- $\beta 3$), or a salt thereof, comprising the step of treating the denatured monomeric form of said TGF- $\beta 2$ or $\beta 3$ with a folding buffer, wherein said folding buffer consists ~~ing essentially~~ of glutathione in its reduced form and an organic solvent which is DMSO (Dimethylsulfoxide) or DMF (Dimethylformamide) or a mixture of DMSO and DMF; ~~wherein said folding buffer does not contain a chaotropic agent~~, thereby permitting folding of the monomeric TGF- $\beta 2$ or $\beta 3$ into the spatial conformation which is associated with the biological activity, while retaining said monomer in a soluble form.

27. (previously presented) The process according to claim 26 in which DMSO is used at a concentration of about 30% to about 50% (vol/vol).

28. (previously presented) The process according to claim 26 in which DMF is used at a concentration of 40% (vol/vol).

29. (previously presented) The process according to claim 26 wherein the organic solvent is a mixture of DMSO and DMF and the mixture is used in a concentration of 10% to about 50%(vol/vol).

30. (previously presented) The process according to claim 26 in which the buffer has a pH of about 8.5 to about 10.

31. (previously presented) The process according to claim 26 in which the buffer has a temperature of about 0°C to about 40°C.

32. (previously presented) The process according to claim 26 in which the reduced glutathione is used in a concentration of about 1 mM to 100 mM.